337526-52-0

Upstream product

• 852409-38-2 ethyl α-(6-chloro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)-α-oxoacetate 
• 5446-18-4 2,4-dichlorophenyl hydrazine hydrochloride 
• 26673-31-4 6-chloro-3,4-dihydronaphthalen-1(2H)-one 
• 337526-51-9 ethyl ester of 6-chloro-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl-(2,4-dichlorophenylhydrazono)acetic acid 

Downstream Products

• 337526-53-1 7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxylic acid 

Relevant academic research and scientific papers

Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same

The subject of the invention is tricyclic derivatives of pyrazolecarboxylic acid of formula: in which R1 represents a C3-C15 carboxyl radical or an NR2R3 group. The invention also relates to the method for preparing the compounds of formula (I), pharmaceutical compositions containing them. The compounds of formula (I) are active on cannabinoid CB1 receptors.

Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors

A series of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides (2a-k) as analogues of the previously reported CB2 ligands 6-chloro- and 6-methyl-1-(2′,4′-dichlorophenyl)-N-piperidin-1-yl-1, 4-dihydroindeno[1,2-c]pyrazole-3-carboxamides (1a,b) was synthesized and their affinity and selectivity towards CB1 and CB2 receptors were evaluated. Several of the new compounds (2a,b,c,d and i) exhibited CB 1 affinity in the nanomolar range with moderate or negligible affinity towards CB2 receptors. Compounds 2a and c increased intestinal propulsion in mouse. Their pro-kinetic effects were reversed by the reference CB agonist CP-55,940. Consequently, in vivo CB1 antagonistic activity was highlighted for these compounds.